Lightweight ResGRU: a deep learning-based prediction of SARS-CoV-2 (COVID-19) and its severity classification using multimodal chest radiography images.

Researchers

Journal

Modalities

Models

Abstract

The new COVID-19 emerged in a town in China named Wuhan in December 2019, and since then, this deadly virus has infected 324 million people worldwide and caused 5.53 million deaths by January 2022. Because of the rapid spread of this pandemic, different countries are facing the problem of a shortage of resources, such as medical test kits and ventilators, as the number of cases increased uncontrollably. Therefore, developing a readily available, low-priced, and automated approach for COVID-19 identification is the need of the hour. The proposed study uses chest radiography images (CRIs) such as X-rays and computed tomography (CTs) to detect chest infections, as these modalities contain important information about chest infections. This research introduces a novel hybrid deep learning model named Lightweight ResGRU that uses residual blocks and a bidirectional gated recurrent unit to diagnose non-COVID and COVID-19 infections using pre-processed CRIs. Lightweight ResGRU is used for multi-modal two-class classification (normal and COVID-19), three-class classification (normal, COVID-19, and viral pneumonia), four-class classification (normal, COVID-19, viral pneumonia, and bacterial pneumonia), and COVID-19 severity types’ classification (i.e., atypical appearance, indeterminate appearance, typical appearance, and negative for pneumonia). The proposed architecture achieved f-measure of 99.0%, 98.4%, 91.0%, and 80.5% for two-class, three-class, four-class, and COVID-19 severity level classifications, respectively, on unseen data. A large dataset is created by combining and changing different publicly available datasets. The results prove that radiologists can adopt this method to screen chest infections where test kits are limited.© The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.